<var id="ndj7z"><video id="ndj7z"><thead id="ndj7z"></thead></video></var>
<menuitem id="ndj7z"><strike id="ndj7z"><thead id="ndj7z"></thead></strike></menuitem>
<var id="ndj7z"></var>
<var id="ndj7z"><video id="ndj7z"></video></var>
<cite id="ndj7z"></cite>
<var id="ndj7z"></var>
<var id="ndj7z"></var>
<cite id="ndj7z"><strike id="ndj7z"><menuitem id="ndj7z"></menuitem></strike></cite> <cite id="ndj7z"><video id="ndj7z"></video></cite>
<cite id="ndj7z"><video id="ndj7z"><menuitem id="ndj7z"></menuitem></video></cite>
<var id="ndj7z"><strike id="ndj7z"></strike></var><var id="ndj7z"></var>
您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 云徑平

    職務:病理科主任,廣東省臨床重點??茖W科帶頭人。
    職稱:教授/主任醫師,博士生導師
    專長:腫瘤生物學和腫瘤分子病理學
        博士(中國香港),教授/主任醫師,博士生導師,病理科主任。 
    學習簡歷:
      1980.9-1985.6:湖南醫科大學,醫學本科.    
      1988.9-1991.6中山醫科大學病理教研室,碩士
      1997.1-7      香港中文大學病理學系  外科病理進修
      1998.3-2001.3 香港中文大學病理學系  博士

    工作簡歷:
      1985.7-1988.8  湖南醫科大學病理教研室任職助教
      1991.7-1998.3  中山大學腫瘤防治中心病理科任醫師和主治醫師
      2001.3-至今   中山大學腫瘤防治中心病理科任主治醫師、副教授及教授/主任醫師。

    臨床工作:
      專長于腫瘤病理診斷。

      1985年本科畢業于湖南醫科大學(現中南大學湘雅醫學院),畢業后一直從事病理學的醫教研工作,先后在中山醫科大學病理教研室和香港中文大學病理學系獲得碩士和博士學位。1991年入職于中山大學腫瘤醫院病理科擔任病理醫生,1997年在香港威爾斯親王醫院進修臨床病理診斷。臨床醫療擅長于腫瘤病理診斷,教學主講本科生和研究生的《腫瘤病理學》課程,科研上主要研究腫瘤發生發展的分子機制及分子分型,已獲得包括5項國家自然基金在內的省部級科研項目16項。發表文章近70篇,其中以第一作者或通訊作者發表SCI文章近30篇。
      目前擔任中國抗癌協會腫瘤專業委員會常委,廣東省抗癌協會腫瘤病理專業委員會主任委員,廣東省醫師病理分會副主任委員、廣東省醫學會病理專業委員會常務委員以及廣東省抗癌協會小兒腫瘤專業委員會常務委員,并擔任三本專業雜志編委:《癌癥》、《中華腫瘤防治雜志》、《腫瘤防治研究》。

    近年主持的研究課題:
      (1) 國家自然基金(81372572):P2-HNF4α促進肝癌細胞增殖的分子機制;2014.1-2017.12。
      (2) 國家自然基金:81172345/H1617;miR-663在肝癌細胞增殖中的作用及分子機制研究。2012.01~2015.12。
      (3) 國家自然基金:編號:30973506;MiRNA靶向MIF及其在鼻咽癌浸潤轉移作用。2009-2011。

    近期發表的主要文章:

      1, Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, Yi C, Fu J, Hu W, Wen JM, Yun JP. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. Oncogene 2015;34:965-77.
      2, Hu W, Lu SX, Li M, Zhang C, Liu LL, Fu J, Jin JT, Luo RZ, Zhang CZ, Yun JP. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma. Oncotarget 2015;6:6570-83.
      3, Zhang CZ, Fang EF, Zhang HT, Liu LL, Yun JP. Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. Invest New Drugs 2015;33:1-11.
      4, Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ, Yun JP. miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis 2014;35:469-78.
      5, Liu LL, Lu SX, Li M, Li LZ, Fu J, Hu W, Yang YZ, Luo RZ, Zhang CZ, Yun JP. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget 2014;5:5113-24.
      6, Liu LL, Zhang MF, Pan YH, Yun JP, Zhang CZ. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Tumour Biol 2014;35:1763-74.
      7, Liu LL, Zhang MF, Pan YH, Yun JP, Zhang CZ. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Tumour Biol 2014
      8, Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J, Zhang CZ. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci 2013;104:508-15.
      9, Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H, Zeng M, Ma J, Zeng Y, Yun JP. MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma. Oncogene 2012;31:4421-33.
      10, Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 2012;10:106.
      11, Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB, Hou JH, Yun JP. Overexpression of ZEB2 in peritumoral liver tissue correlates with favorable survival after curative resection of hepatocellular carcinoma. PLoS One 2012;7:e32838.
      12, Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo RZ, Shao JY, He Z, Zeng YX, Kang T, Yun JP, Xie F. Prognostic significance of SOX2 expression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85.
      13, Li JD, Zhuang Y, Li YF, Feng YL, Hou JH, Chen L, Zhu AN, Wu QL, Yun JP. A clinicopathological aspect of primary small-cell carcinoma of the uterine cervix: a single-centre study of 25 cases. J Clin Pathol 2011;64:1102-7.
      14, Zhang MF, Lin SX, Yi C, Fu J, Wu QL, Yun JP. Keratocystoma of the parotid gland: case report and immunohistochemical investigation. J Clin Pathol 2010;63:758-60.
      15, Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 2009;7:110.
      16, Xiao J, Zhang Z, Chen GG, Zhang M, Ding Y, Fu J, Li M, Yun JP. Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. Cell Cycle 2009;8:889-95.
      17, Luo R, Zhang M, Liu L, Lu S, Zhang CZ, Yun J. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One 2013;8:e70511.
      18, Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun J. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 2012;7:e51703.
      19, Zhang CZ, Pan Y, Cao Y, Lai PB, Liu L, Chen GG, Yun J. Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo. PLoS One 2012;7:e39870.
      20, Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012;7:e41293.
      21, Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 2012;83:1278-89.
      22, Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010;51:836-45.
      23, Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
      24, Kuang DM, Zhao Q, Xu J, Yun JP, Wu C, Zheng L. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J Immunol 2008;181:3089-98.
      25, Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, Wu QL, Rong TH. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. BMC Cancer 2007;7:38.
      26, Yun JP, Miao J, Chen GG, Tian QH, Zhang CQ, Xiang J, Fu J, Lai PB. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer 2007;96:477-8.
      27, Yun JP, Xiang J, Hou JH, Tian QH, Fu J. [Expression of CD56, as a potential diagnostic marker, in small cell carcinoma]. Ai Zheng 2005;24:1140-3.
      28, Yun JP, Liew CT, Chew EC, Yin XY, Lai PB, Fai YH, Li HK, Jin ML, Ding MX, Li MT, Lin HL, Lau WY. Nuclear matrix protein expressions in hepatocytes of normal and cirrhotic rat livers under normal and regenerating conditions. J Cell Biochem 2004;91:1269-79.
      29, Yun JP, Chew EC, Liew CT, Chan JY, Jin ML, Ding MX, Fai YH, Li HK, Liang XM, Wu QL. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem 2003;90:1140-8.


             更新時間:2015.6.25

訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
沙巴体育下载